Press Releases

Date Title and Summary Additional Formats
Toggle Summary Evoke Pharma Announces Full Exercise of Underwriters' Over-Allotment Option
SAN DIEGO , Oct. 3, 2013 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the full exercise of the over-allotment option granted to the representative of the underwriters to purchase an
View HTML
Toggle Summary Evoke Pharma Announces Initiation of a Thorough ECG (QT) Study for EVK-001
SOLANA BEACH, Calif. , Aug. 12, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the initiation of its thorough ECG (QT) study of the Company's lead product candidate, EVK-001,
View HTML
Toggle Summary Evoke Pharma Announces Issuance of a New U.S. Patent Covering Methods of Use for Gimoti®
New patent expands intellectual property protection for nasal delivery of metoclopramide and is expected to be FDA Orange Book listed SOLANA BEACH, Calif. , June 02, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for
View HTML
Toggle Summary Evoke Pharma Announces Key Opinion Leader Fireside Chat to Discuss Gastroparesis Treatment Landscape
SOLANA BEACH, Calif. , March 10, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases, today announced that together with the research team at H.C. Wainwright & Co.
View HTML
Toggle Summary Evoke Pharma Announces Positive Findings from GIMOTI™ Market Research Study
Healthcare practitioner survey indicates physicians’ awareness and intent to prescribe newly-launched product SOLANA BEACH, Calif. , Jan. 13, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (“Evoke” or the “Company”) (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for
View HTML
Toggle Summary Evoke Pharma Announces Positive Non-Clinical Pre-NDA Meeting with FDA for Gimoti
SOLANA BEACH, Calif., Sept. 07, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK) (the "Company"), a specialty pharmaceutical company focused on treatments for gastrointestinal diseases, today announced that it has completed a pre‑New Drug Application (NDA) meeting with the U.S.
View HTML
Toggle Summary Evoke Pharma Announces Positive Topline Results from Comparative Exposure Pharmacokinetic Study for Gimoti™
505(b)(2) NDA on track for FDA submission in Q1 2018
View HTML
Toggle Summary Evoke Pharma Announces Pricing of Initial Public Offering of 2,100,000 Shares of Common Stock
SAN DIEGO, CA, September 24, 2013 – Evoke Pharma, Inc., a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the pricing of its initial public offering of 2,100,000 shares of its common stock at a public offering price of $12.00 per
View HTML
Toggle Summary Evoke Pharma Announces Pricing of Public Offering of Common Stock
SOLANA BEACH, Calif., Feb. 16, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal diseases, announced today that it has priced an underwritten public offering of 2,413,793 shares of its common stock at a price to
View HTML
Toggle Summary Evoke Pharma Announces Pricing of Public Offering of Common Stock
SOLANA BEACH, Calif. , Jan. 13, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced that it has priced an underwritten public offering of 5,000,000 shares of its common
View HTML